

Freedom of Information Act 2000 - Request Reference Fol/22/289
Dabrafenib + Trametinib for Cancer

Information Requested:

- 1) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
 - i) Metastatic Melanoma
 - ii) Adjuvant Melanoma
 - iii) BRAF mutated Lung Cancer

Response details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that these treatments are provided by Velindre Cancer Centre, please see their contact details below:

foi.vunhst@wales.nhs.uk

Or,

Velindre NHS Trust Headquarters.
Unit 2 Charnwood Court,
Parc Nantgarw,
Nantgarw,
Cardiff.
CF15 7QZ